Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

被引:50
作者
Semple, Sean C. [1 ]
Leone, Robert [1 ]
Barbosa, Christopher J. [1 ]
Tam, Ying K. [1 ]
Lin, Paulo J. C. [1 ]
机构
[1] Acuitas Therapeut, 6190 Agronomy Rd, Vancouver, BC V6T 1Z3, Canada
关键词
lipid nanoparticles; siRNA-LNP; mRNA-LNP; prophylactic vaccines; gene editing; mRNA-based therapeutics; INDEPENDENT GENE SUPPRESSION; IN-VIVO; ANTISENSE OLIGONUCLEOTIDES; INTRACELLULAR DELIVERY; EXPRESSION KINETICS; CATIONIC LIPIDS; RABIES VACCINE; OPEN-LABEL; SIRNA; TRANSFECTION;
D O I
10.3390/pharmaceutics14020398
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2 infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of candidates was evaluated, with mRNA-based vaccines emerging as leaders due to how quickly they were available for emergency use while providing a high level of efficacy. As a modular technology, the mRNA-based vaccines benefitted from decades of advancements in both mRNA and delivery technology prior to the current global pandemic. The fundamental lessons of the utility of mRNA as a therapeutic were pioneered by Dr. Katalin Kariko and her colleagues, perhaps most notably in collaboration with Drew Weissman at University of Pennsylvania, and this foundational work paved the way for the development of the first ever mRNA-based therapeutic authorized for human use, COMIRNATY(R). In this Special Issue of Pharmaceutics, we will be honoring Dr. Kariko for her great contributions to the mRNA technology to treat diseases with unmet needs. In this review article, we will focus on the delivery platform, the lipid nanoparticle (LNP) carrier, which allowed the potential of mRNA therapeutics to be realized. Similar to the mRNA technology, the development of LNP systems has been ongoing for decades before culminating in the success of the first clinically approved siRNA-LNP product, ONPATTRO(R), a treatment for an otherwise fatal genetic disease called transthyretin amyloidosis. Lessons learned from the siRNA-LNP experience enabled the translation into the mRNA platform with the eventual authorization and approval of the mRNA-LNP vaccines against COVID-19. This marks the beginning of mRNA-LNP as a pharmaceutical option to treat genetic diseases.
引用
收藏
页数:23
相关论文
共 50 条
[41]   From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases [J].
Pilkington, Emily H. ;
Suys, Estelle J. A. ;
Trevaskis, Natalie L. ;
Wheatley, Adam K. ;
Zukancic, Danijela ;
Algarni, Azizah ;
Al-Wassiti, Hareth ;
Davis, Thomas P. ;
Pouton, Colin W. ;
Kent, Stephen J. ;
Truong, Nghia P. .
ACTA BIOMATERIALIA, 2021, 131 :16-40
[42]   Nanoparticle-based delivery of RNA therapeutics [J].
Cicha, Iwona ;
Spielvogel, Helmut ;
Tietze, Rainer ;
Lyer, Stefan ;
Janko, Christina ;
Civelek, Mehtap ;
Alexiou, Christoph .
NANOMEDICINE, 2025, 20 (12) :1385-1389
[43]   Current landscape of mRNA technologies and delivery systems for new modality therapeutics [J].
Lu, Ruei-Min ;
Hsu, Hsiang-En ;
Perez, Ser John Lynon P. ;
Kumari, Monika ;
Chen, Guan-Hong ;
Hong, Ming-Hsiang ;
Lin, Yin-Shiou ;
Liu, Ching-Hang ;
Ko, Shih-Han ;
Concio, Christian Angelo P. ;
Su, Yi-Jen ;
Chang, Yi-Han ;
Li, Wen-Shan ;
Wu, Han-Chung .
JOURNAL OF BIOMEDICAL SCIENCE, 2024, 31 (01)
[44]   Optimal delivery strategies for nanoparticle-mediated mRNA delivery [J].
Li, Xiaoyan ;
Guo, Xiaocui ;
Hu, Mingdi ;
Cai, Rong ;
Chen, Chunying .
JOURNAL OF MATERIALS CHEMISTRY B, 2023, 11 (10) :2063-2077
[45]   Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles [J].
Bost, Jeremy P. ;
Barriga, Hanna ;
Holme, Margaret N. ;
Gallud, Audrey ;
Maugeri, Marco ;
Gupta, Dhanu ;
Lehto, Taavi ;
Valadi, Hadi ;
Esbjorner, Elin K. ;
Stevens, Molly M. ;
El-Andaloussi, Samir .
ACS NANO, 2021, 15 (09) :13993-14021
[46]   Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery [J].
Maeki, Masatoshi ;
Uno, Shuya ;
Niwa, Ayuka ;
Okada, Yuto ;
Tokeshi, Manabu .
JOURNAL OF CONTROLLED RELEASE, 2022, 344 :80-96
[47]   A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery [J].
Meyer, Randall A. ;
Hussmann, G. Patrick ;
Peterson, Norman C. ;
Santos, Jose Luis ;
Tuesca, Anthony D. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 611
[48]   Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle-Based Gene Delivery Systems [J].
Greco, Antonietta ;
Corbo, Claudia .
SMALL SCIENCE, 2025,
[49]   A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo [J].
Hajj, Khalid A. ;
Melamed, Jilian R. ;
Chaudhary, Namit ;
Lamson, Nicholas G. ;
Ball, Rebecca L. ;
Yerneni, Saigopalakrishna S. ;
Whitehead, Kathryn A. .
NANO LETTERS, 2020, 20 (07) :5167-5175
[50]   Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA? [J].
Tam, Ying K. ;
Madden, Thomas D. ;
Hope, Michael J. .
JOURNAL OF DRUG TARGETING, 2016, 24 (09) :774-779